Advertisement
Advertisement
CORT
Corcept Therapeutics Inc.
56.37
USDSponsored
-1.93
-3.31%
May 15, 15:59 UTC -4
Closed
After-Market
57.49
+1.12
+1.99%
CORT Earnings Reports
Positive Surprise Ratio
CORT beat 26 of 42 last estimates.
62%
Next Report
Date of Next Report
Jul 29, 2026
Estimate for Q2 26 (Revenue/ EPS)
$221.85M
/$0.04
Implied change from Q1 26 (Revenue/ EPS)
+34.53%
/-113.33%
Implied change from Q2 25 (Revenue/ EPS)
+14.10%
/-85.71%
Corcept Therapeutics Inc. earnings per share and revenue
On Apr 30, 2026, CORT reported earnings of -0.30 USD per share (EPS) for Q1 26, missing the estimate of -0.01 USD, resulting in a -1530.43% surprise. Revenue reached 164.90 million, compared to an expected 196.36 million, with a -16.02% difference. The market reacted with a +10.53% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of 0.04 USD, with revenue projected to reach 221.85 million USD, implying an decrease of -113.33% EPS, and increase of 34.53% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
May 13, 2026 For Q4 26
Estimate
-$24.25
Actual
$44.19
Surprise
+282.20%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.51
Actual
-$0.61
Surprise
-19.51%
Aquestive Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+49.96%
Altimmune, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.24
Actual
-$0.18
Surprise
+27.18%
Prelude Therapeutics Incorporated
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.13
Surprise
+48.68%
Achieve Life Sciences, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.19
Surprise
+39.59%
Karyopharm Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.45
Actual
-$1.24
Surprise
+14.90%
Journey Medical Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-1.14%
Avita Medical, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.28
Actual
-$0.35
Surprise
-22.55%
PolyPid Ltd. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.81%
FAQ
What were Corcept Therapeutics Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Corcept Therapeutics Inc. reported EPS of -$0.30, missing estimates by -1530.43%, and revenue of $164.90M, -16.02% below expectations.
How did the market react to Corcept Therapeutics Inc.'s Q1 2026 earnings?
The stock price moved up 10.53%, changed from $46.52 before the earnings release to $51.42 the day after.
When is Corcept Therapeutics Inc. expected to report next?
The next earning report is scheduled for Jul 29, 2026.
What are the forecasts for Corcept Therapeutics Inc.'s next earnings report?
Based on 7
analysts, Corcept Therapeutics Inc. is expected to report EPS of $0.04 and revenue of $221.85M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement